GlassScriptPhysician profile
Laura June Eaglen
NPI 1790047637
$2,368.53
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $1,657 · 2023: $288 · 2024: $79.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.84 | 2021-2024 | |
| Boston Scientific Corporation | $475.18 | 2021-2024 | Exalt Model D, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $333.63 | 2021-2022 | |
| Erbe USA INC | $142.66 | 2023 | Erbe Apc Ed |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.38 | 2022 | |
| Ardelyx, INC. | $120.72 | 2022 | |
| Nestle Healthcare Nutrition INC. | $91.58 | 2021-2022 | |
| Qol Medical, LLC | $85.86 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $75.58 | 2022 | |
| Intra-Sana Laboratories | $72.65 | 2021-2022 | |
| Gilead Sciences, INC. | $50.10 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $36.68 | 2022 | |
| Merck Sharp & Dohme LLC | $31.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.37 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.64 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.63 | 2022 | |
| Pfizer INC. | $18.53 | 2022 | |
| Braintree Laboratories, INC. | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Eaglen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.